Coloplast A/S Interim Financial Report H1 2025/26

Coloplast A/S reported its interim financial results for the first half of fiscal year 2025/26, revealing a Q2 organic growth of 6% and EBIT growth of 6% in constant currencies. While the company saw strong growth in areas like Ostomy Care, Continence Care, Voice & Respiratory Care, and Interventional Urology, it faced challenges in Wound & Tissue Repair due to negative impacts from currency fluctuations and product returns. The total reported revenue grew by 1%, and the EBIT margin was 26%. The company recognized a significant impairment loss on its Kerecis goodwill, reducing its carrying value significantly. For FY 2025/26, Coloplast anticipates organic revenue growth of 5-6% and EBIT growth of around 5%.